Should law and public policy adopt 'practical causality' as the appropriate criteria for deciding product liability cases and public policy?

Law, Probability and Risk

Volumn 12, Issue 3-4, 2013, Pages 169-188

  Gastwirth, Joseph L ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Bayesian inference; Causality; Epidemiology as evidence; Omitted variable; Preponderance of the evidence; Product liability; Reye syndrome; Substantial evidence

Indexed keywords

EID: 84887668807     PISSN: 14708396     EISSN: 1470840X     Source Type: Journal    
DOI: 10.1093/lpr/mgt006     Document Type: Article

References (54)

1. APFEL, R. J. & FISHER, S. M. (1984). To Do No Harm: DES and the Dilemmas of Modern Medicine. Yale University Press, New Haven.
2. BERGER, R. L. & BOOS, DENNIS D. (1994). Values maximized over a confidence set for the nuisance parameter. J. Amer. Stat. Assoc., 89, 1012-1016.
3. CARRUTH, R. S. & GOLDSTEIN, B. D. (2001). Relative risk greater than two in proof of causation in toxic tort litigation. Jurimetrics, 41, 195-210.
4. CDC (1985). Update-Reye syndrome pilot study-United States, 1984. Morbidity and Mortality Weekly Report, 34, 13-16.
5. CDC (1986). Reye syndrome-1985. Morbidity and Mortality Weekly Report, 35, 66-68.
6. CHRISTIANSON, R., JOHNSON, W. O., BRANSCUM, A. & HANSON, T. (2010). Bayesian Ideas and Data Analysis: An Introduction for Scientists and Statisticians. CRC Press, Boca Raton, FL.
7. DAWID, A. (2000). Causal inference without counterfactuals. JASA, 95, 407-424.
8. FDA (1982). Labeling for Salicylate-Containing Drug Products. Federal Register, 47, 28 December 1982, 57886-57901.
9. FDA Drug Safety Communication (2001). Announcing baycol withdrawal.
10. FDA Drug Safety Communication (2012). Important safety label changes to cholesterol-lowering statin drugs. 28 February 2012.
11. FEYNMAN, R.P. (1963, 1998).TheMeaning of itAll: Thoughts ofaCitizen Scientist.Addison-Wesley,Reading,MA.
12. FORSYTH, B.W., HORWITZ, R. I.,ACAMPO, D. et al. (1989). New epidemiologic evidence confirming that bias does not explain the aspirin/Reye's syndrome association. JAMA, 261, 2517-2524.
13. GASTWIRTH, J. L. (1992). Statistical reasoning in the legal setting. American Statistician, 46, 55-69.
14. GASTWIRTH, J. L. (1988a). Statistical Reasoning in Law and Public Policy: Vol. 1. Statistical Concepts and Issues of Fairness. Academic Press, Boca Raton, FL.
15. GASTWIRTH, J. L. (1988b). Statistical Reasoning in Law and Public Policy: Vol. 2. Tort Law, Evidence and Health. Academic Press, Boca Raton, FL.
16. GASTWIRTH, J. L. (2012a). Statistical considerations support the Supreme Court's decision in Matrixx Initiatives v. Siracusano. Jurimetrics, 52, 155-175.
17. Gastwirth, J.L. (2012b). The need for courts and policy makers to carefully evaluate criticisms of statistical evidence. 16 (www.i-lex.it).
18. GOLD, S. (1986). Causation in toxic torts: burdens of proof, standards of persuasion, and statistical evidence. Yale L. J., 96, 376-402.
19. GREEN, M. D. (1988). The paradox of statutes of limitations in toxic substances litigation. California L. Rev., 76, 965-1022.
20. GREENHOUSE, S. W. (1982). Jerome Cornfield's contributions to epidemiology. Biometrics, 38(Suppl.), 33-46.
21. GREENLAND, S. & ROBBINS, J. M. (2000). Epidemiology, justice and the probability of causation. Jurimetrics, 40, 321-338.
22. HALPIN, T.H.,HOLTZHAUER, F. J.,CAMPBELL, R. J. et al. (1982). Reye's syndrome and medication use. J. Am.Med. Assoc., 248, 687-691.
23. HARDIE, R. M., NEWTON, H., BRUCE, J. C., GLASGOW, J. F.T., MOWAT, A. P., STEPHENSON, J. B.P & HALL, S. M. (1996). The changing clinical pattern of Reye's syndrome 1882-1990. ADC, 74, 400-405.
24. HECKMAN, J. J. (2008). Econometric causality. Inter. Stat. Rev., 76, 1-27.
25. HENDERSON, J. A. JR & TWERSKI, A. D. (2011). Products Liability: Problems and Process. 7th edn. Wolters & Kluwer, New York, NY.
26. HILL, A. B. (1965). The environment and health: association or causation. Proc. R. Soc. Med., 58, 295-300.
27. HOLLAND, P. W. (1986). Statistics and causal inference. J. Am. Stat. Assoc., 81, 945-960.
28. HURWITZ, E. S., BARRETT, M. J., BREGMAN, D. et al. (1987). Public health service study of Reye's syndrome and medications: report of the main study. JAMA, 257, 1905-1911.
29. KADANE, J. B. (1990). A statistical analysis of adverse impact of employer decisions. J. Am. Stat. Assoc., 85, 925-933.
30. KJELLSTROM, T., FRIBERG, L. & RAHNSTER, B. (1979). Mortality and cancer morbidity among cadmium-exposed workers. EHP, 28, 199-204.
31. LINNEMANN, C. JR, SHEA, L., PARTIN, J. C., SCHUBERT, W. K. & SCHIFF, G. M. (1975). Reye's syndrome: Epidemiologic and viral studies, 1963-1974. Am J. Epidemiol., 101, 517-526.
32. LOUE, S. (2000). Epidemiological causation in the legal context: substance and procedures. Statistical Science in the Courtroom, (J.L.Gastwirth ed.). New York, NY: Springer.
33. MENGERSON, K., MOYNIHAN, S. A. & TWEEDIE, R. L. (2007). Causality and association: The statistical and legal approaches. Stat. Sci., 22, 227-254.
34. OAKSFORD, M. & CHATER, N. (2007). Bayesian Rationality. Oxford University Press, Oxford, UK.
35. OGOLLA, C. (2010). What are the policy implication so use of epidemiological evidence in mass torts and public health litigation? St. Thomas L. Rev., 23, 159-188.
36. OWEN, D. G. (2008). Products Liability Law. 2nd edn. Thomson/West, St. Paul, MN.
37. PEARL, J. (2000). Causality. Cambridge University Press, Cambridge, UK.
38. PHILLIPS, J. J. (1978). An analysis of proposed reform of products liability statutes of limitations. North Carolina L. Rev., 56, 663-676.
39. POPPER, K. (1959). The Logic of Scientific Discovery. Harper & Row, New York.
40. Public Health Service (1985). Public Health service study on Reye's syndrome and medications. New England J. Med., 313, 849-857.
41. ROSENBAUM, P. R. (2002). Observational Studies, 2nd edn. Springer, NY.
42. ROSS, K.&PRINCE, J. D. (2009). Post-sale duties: themost expansive theory in products liability. Brooklyn L. Rev., 74, 963-986.
43. ROTH-CLINE,M. D. (2006). Clinical trials in the wake of Vioxx: requiring statistically extreme evidence of benefit to ensure safety of new drugs. Circulation, 113, 2253-2259.
44. SAHMOUN, A. E., CASE, L.D., JACKSON, S.A. & SCHWARTZ, C. G. (2005). Cadmium and prostate cancer: a critical epidemiologic analysis. Cancer Investigation, 23, 256-263.
45. SEIGEL, D.G.&GREENHOUSE, S.W. (1973). Validity in estimating relative risk in case control studies. J. Chronic Diseases, 26, 218-225.
46. SIEGEL, R., NASIHADHAM, D.&JEMAL, A. (2012). Cancer Statistics, 2012. CA: A Cancer J. Clinicians, 62, 10-29.
47. STARKO, K.M.,RAY, C.G.,DOMINGUEZ, L.B., STROMBERG, W. L. &WOODALL, D. F. (1980). Reye's syndrome and salicylate use. Pediatrics, 66, 859-864.
48. TARONI, F., BOZZA, S.,BIEDERMANN, A.,GARBOLINO, P.&AITKEN, C. (2010). Data Analysis in Forensic Science: A Bayesian Decision Perspective. John Wiley, Chichester, UK.
49. TWERSKI, A. D. (1997). Inside the restatement. Pepperdine L. Rev., 24, 839-857.
50. VISCUSI,W. K. (1990). Wading through the muddle of risk-utility analysis. American Univ. L. Rev., 39, 573-614.
51. WALDMAN, R. J.,HALL, W. N.,MCGEE, H.&VAN AMBURG, G. (1982). Aspirin as a risk factor in Reye's syndrome. JAMA, 247, 3089-3094.
52. WILSON, J.T.&BROWN, R. D. (1982). Reye Syndrome and aspirin use: the role of prodromal illness severity in the assessment of relative risk. Pediatrics, 69, 822-825.
53. YOUNG, R. S., TORRETTI, D.,WILLIAMS, R. H., HENDRICKSON, D. & WOODS, M. (1984). Reye syndrome associated with long-term aspirin therapy. JAMA, 251, 754-756.
54. ZHANG, Q. (2006). The financial and marketing impact of catastrophic product failure: a study of prescription drug withdrawals. Ph.D. dissertation. University of Georgia.